1Volock DR, et al. Incidence of serurn antibody reactivity to autologous head and neck cancer cell lines and augmentaion of antibody reactivity following acid dissociation and ultuafiltration[J],Cancer Res, 1982,42:4110.
2Guadagni F, Roselli M, Cosimelli M, Mannella E, et al. TAG-72(CA72-4 assay) as a complementary serum tumor antigon to carcinoembryonic antigen in monitoring patients with colorectal cancer[J]. Cancer, 1993,72(7) :2098.
3Minton JP, Hoehn JL, Greler DM, Re,lts of 400 patients carcints carcinoem bryonic antigen second look colorectal study[J]. Cancer, 1985,55(1):284.
4Kahhoff H, etal, Charcteriation of CA19-9 besring mucins as physiologyical exocrine pancreatic products[J]. Cancer Res, 1986,46:3605.
5Hanisch FG, et al. CA125 and CA19-9:Two cancer associated sialysacharide antigens on a mucus 81ycoprotein from haman milk [J]. Eur J Biochem, 1985,149:323.
6Stocchi, Luca M, D., Nelson, Heidi M. D. Diagnostic and Therapeutic Applications of Monoclonal Antibodies in Colorectal Cancer[J]. Diseases of the Colon & Rectum, 1998,41(2):232.
7Guadagni F, Roselli M, AmatoT, et al. Clinical evaluation of serum tumor- associated glycoprotein-72 as a nowel tumor marker for colorectal cancer patients[J]. J Surg Oncol Suppl, 1991,2:16.
8Ohuchi N, Matoba N, Taira Y, etal. Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4[J]. Gan To Kagaku Ryoho, 1988,15(9) :2767.
9Rittenhouse HG, et al. Mucin-type glycoprotein as tumor markers[J].Lab Med, 1985,15:556.
10Shuster J, et al. Metabolism of human carcinoembryonlc antigen in xenogenyic animals[J]. Cancer res, 1973,33:65.
